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Abstract
Introduction: When a standard dose of statins fails to achieve lipid control in
patients at high risk for coronary artery disease (CAD), increasing the statin
dosage or co-administration of additional agents is recommended. The aim of
this study was to compare the safety and lipid-lowering efficacy of doubling the
standard statin dose (STAT2) to that of co-administering ezetimibe 10 mg/day
(EZE + statin) in Canadian patients at high CAD risk with persistent hyper  li  pi  -
demia upon statin treatment. 
Material and methods: Six-week, open-label, randomized, multicentre study.
The primary outcome was the change in plasma LDL-C and secondary measures
included the change in additional lipid parameters. Safety was assessed with
the incidence of emergent adverse events (AEs).
Results: Eight hundred eighty-five patients (EZE + statin, n = 586; STAT2, 
n = 299) completed the study. The mean (SD) percent change in low-density
lipoprotein cholesterol (LDL-C) was – 30.9% (18.2) for the EZE + statin group and
–18.4% (19.0) for the STAT2 group (p = 0.001). Percent and absolute decreases
in total cholesterol (TC), triglycerides and the TC to high-density lipoprotein
cholesterol ratio (TC/HDL-C) were significantly greater for the EZE + statin group
(p = 0.001). After 6 weeks of treatment, 70% of the patients in the EZE + statin
group and 48% of patients in the STAT2 group (OR = 2.45, p < 0.001) achieved
target LDL-C levels of < 2.5 mmol/l. Incidence of AEs was similar between groups,
with the exception of a higher incidence of muscle disorders in the STAT2 group.
Conclusions: In patients at high CAD risk who are above the LDL-C target while
on statin monotherapy, co-administration of ezetimibe is well tolerated and
more effective in improving the lipid profile compared to doubling the existing
statin dose.
Key words: ezetimibe, hypercholesterolemia, low-density lipoprotein cholesterol,
statin.
Introduction 
Cardiovascular disease is the major cause of death globally, accounting
for 29% of all deaths, and its prevalence is expected to increase within the
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next 2 decades [1]. The importance of hyper  -
cholesterolemia in increasing the risk of developing
cardiovascular artery disease (CAD) has been well
documented by numerous epide  miological studies
[2, 3]. Currently, the gold standard for treating CAD
involves modifications in lifestyle and pharma  -
cological intervention with statins to reduce the low-
density lipoprotein cholesterol (LDL-C). For a large
number of patients, however, statin monotherapy is
not effective in achieving target LDL-C levels [4-6].
For these patients, titration to higher statin doses or
co-administration of additional complementary lipid-
lowering agents is recommended by the Canadian
Cardiovascular Society [7]. 
Ezetimibe is a cholesterol absorption inhibitor
which interferes with the uptake of dietary and
biliary cholesterol from the small intestine [8]. Co-
administration of ezetimibe with statins results in
a greater reduction of LDL-C levels and enhanced
improvement of the lipid profile compared with
statin monotherapy [9-14], while protecting against
the risk of adverse events when using high-dose
statins [15-17].
The purpose of this open-label randomized trial
was to compare, in a real-life setting, the effecti  -
veness and tolerability of ezetimibe 10 mg/day co-
administered with the existing statin regimen
versus doubling of the current statin dose in
patients at high CAD risk who had not achieved
target LDL-C levels while on statin monotherapy. 
Material and methods
Patient population
Male and female adults with a diagnosis of
primary hypercholesterolemia, who were at high risk
for coronary artery disease (as defined by
a Framingham 10-year risk for CAD ≥ 20%, or medical
history of diabetes mellitus and/or atherosclerosis
disease) and had LDL-C ≥ 2.5 mmol/l while on statin
treatment, were eligible for the study [18]. Additional
inclusion criteria included a stable medication
regimen and a stable diet for at least 4 weeks prior
to study screening. Patients were excluded if they
were treated with any other investigational drug
within 30 days prior to study recruitment, had any
clinically significant concomitant disease which
would render them unable to complete the study or
place them at risk, were treated with any medication
that might interact negatively with statins or
ezetimibe or affect the patient’s serum lipid levels
within eight weeks, or experienced myocardial
infarction or coronary intervention within 3 months.
Use of cardiovascular medication was allowed
provided that the dose was stable for at least 
6 weeks prior to study entry and the duration of 
the study. Hormone replacement therapy in women
was also allowed at a stable dose for at least 8 weeks
prior to the screening visit and during the study. 
Study design
This was a 6-week, prospective, randomized,
open-label trial on patients recruited from the
practices of 241 Canadian general practitioners.
Eligible patients signed informed consent prior to
study enrolment. The study was approved by two
independent ethics review boards (IRB services in
Aurora, Ontario, Canada; College of Physicians and
Surgeons of Alberta, Canada). Patients were
assessed for eligibility and underwent a review of
medical history, with emphasis on cardiovascular
history and risk, as well as a review of lipid-lowering
medication use at the screening visit. Baseline 
12-h fasting measurements of LDL-C, total
cholesterol (TC), triglycerides (TG) and high-density
lipoprotein cholesterol (HDL-C) were conducted at
local facilities within three days of the screening
visit. The LDL-C was calculated using the standard
Friedewald estimation method. However, when TG
levels were > 3.99 mmol/L, LDL-C was determined
by ultracentrifugation since high TG levels have
been shown to interfere with the accurate
determination of LDL-C by the Friedewald equation
[19]. Furthermore, direct enzymatic LDL-C assays
which require less time and money have been
shown to overestimate LDL-C when TG values are
greater than 400 mg/dl, leading to misclassification
of the severity of dyslipidemia [20]. 
At the baseline visit, which took place within two
weeks of the screening visit, patients were
randomly assigned in a 1 : 1 ratio to either receive
10 mg/day ezetimibe (Ezetrol®, Merck) co-admi  -
niste  red with their existing statin regimen (EZE +
statin group), or double their current statin dose,
for 6 weeks (STAT2 group). During randomized
allocation the practitioner contacted an Interactive
Voice Response System (IVRS) which issued
a randomization number along with the treatment
allocation. Randomization was centrally coordinated
by a third-party data management center and was
stratified by center. Patients allocated to the STAT2
group, who were on the highest possible dose of
statin or were intolerant of higher statin doses as
per the patient’s or physician’s assessment, were
converted to the EZE + statin group. All patients
were instructed not to change their diet or exercise
habits during the study. There were no limitations
on the type or dose of statin used at baseline.
Ezetimibe was provided at no cost to the patient
while statins were acquired via the existing
insurance coverage. The final study visit took place
6 weeks after the baseline visit. 
Outcome measures
The primary efficacy outcome measure was the
percent change in plasma LDL-C concentration
during the 6-week treatment period. Secondary
efficacy measures included the changes in TC, TG,Arch Med Sci 5, October / 2011 769
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HDL-C and the TC/HDL-C ratio, as well as the
proportion of patients achieving the recommended
target LDL-C of < 2.5 mmol/l (2003 Canadian recom  -
mendations for the management of dyslipidemia
and the prevention of cardiovascular disease [18])
or < 2.0 mmol/l (2009 Canadian guidelines for the
diagnosis and treatment of dyslipidemia and
prevention of cardiovascular disease [7]). Sample
size requirements for the study were based on the
primary efficacy measure. In order to detect
a difference of 15% in the percent plasma LDL-C
change between the two treatment groups with
90% power and 5% significance, a sample size of
90 patients per group or 180 patients in total would
be required. Similarly, for the subgroup analysis
(diabetes and metabolic syndrome subgroup,
diabetes subgroup, metabolic syndrome subgroup,
and subgroup with neither of the two conditions)
180 patients per subgroup would be required.
Based on the patients actually recruited in the
current study (265 patients with diabetes and the
metabolic syndrome, 212 patients with diabetes
only, 106 patients with the metabolic syndrome
only, and 353 patients with neither of the two
Characteristics Treatment groupT otal (n = 936) Value of p
EZE + statin (n = 620) STAT2 (n = 316)
Age
Mean (SD) 63 (11.3) 63 (11.4) 63 (11.3)
0.604
Range 26-89 28-87 26-89
Age categories, n (%)
≤ 45 40 (6.5) 18 (5.7) 58 (6.2)
46-65 334 (53.9) 151 (47.8) 485 (51.8)
0.181
65-85 237 (38.2) 144 (45.6) 381 (40.7)
≥ 85 9 (1.5) 3 (0.9) 12 (1.3)
Gender, n (%)
Male  392 (63.2) 191 (60.4) 583 (62.3)
0.406
Female  228 (36.8) 125 (39.6) 353 (37.7)
Co-morbidity and risk factor profile, n (%)
Smoking status
Current smoker 130 (21.0) 68 (21.5) 198 (21.2)
Ex-smoker 206 (33.2) 95 (30.1) 301 (32.2) 0.611
Non-smoker 284 (45.8) 153 (48.4) 437 (46.7)
Hypertension 345 (55.6) 179 (56.6) 524 (56.0) 0.809
Diabetes mellitus  129 (20.8) 83 (26.3) 212 (22.6) 0.059
Metabolic syndrome 82 (13.2) 24 (7.6) 106 (11.3) 0.010
Diabetes mellitus and metabolic syndrome 174 (28.1) 91 (28.8) 265 (28.3) 0.464
Neither diabetes mellitus nor metabolic syndrome 235 (37.9) 118 (37.3) 353 (37.7) 0.867
Coronary artery disease 262 (42.3) 129 (40.8) 391 (41.8) 0.674
Cerebrovascular disease 73 (11.8) 35 (11.1) 108 (11.5) 0.752
Peripheral vascular disease 60 (9.7) 26 (8.2) 86 (9.2) 0.468
Chronic kidney disease 18 (2.9) 12 (3.8) 30 (3.2) 0.463
Family history of CVD 300 (48.4) 163 (51.6) 463 (49.5) 0.418
Menopausal status (n = 353)
Pre-menopause 15 (6.6) 7 (5.6) 22 (6.2)
Peri-menopause 7 (3.1) 4 (3.2) 11 (3.1) 0.497
Post-menopause 202 (88.6) 114 (91.2) 316 (89.5)
Use of hormone replacement therapy 37 (16.2) 17 (13.6) 54 (15.3) 0.486
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conditions) the statistical power of the current
study was > 0.99 for the total population, the
diabetes and metabolic syndrome subgroup, the
diabetes subgroup and the subgroup with neither
of the two conditions, while it was 0.63 for the
metabolic subgroup.
Safety was assessed with clinical laboratory
parameters and the incidence of treatment-
emergent adverse events that were attributed to
ezetimibe or the statin regimen according to the
treating physician’s judgment. All adverse events
were reported according to the MedDRA dictionary
of terms, version 9 [21]. 
Statistical analysis
The intention-to-treat (ITT) principle, including
all patients who received at least one dose of
ezetimibe or double statin dose, was employed to
analyze the study outcomes. All analyses were
conducted for the total patient population, patients
with diabetes and the metabolic syndrome (as
defined by the 2005 modified International Diabetes
Federation criteria [22]), patients with diabetes only,
patients with the metabolic syndrome only, and
patients with neither of the two conditions, using
the SPSS software, version 12.0. Statistical
significance for between-group differences in
continuous outcomes was assessed with the two-
tailed Student’s t-test for independent samples,
while the non-parametric Mann-Whitney test was
used for patient subgroups. Multiple linear
regression and general linear models (GLM) were
used to assess between-group differences with
respect to the primary efficacy measure (dependent
variable: % change in LDL-C), adjusting for potential
confounders (independent variables: treatment
group, baseline statin dose).
Results
Baseline characteristics
A total of 1,155 patients were screened between
May 2005 and June 2006, among whom 936 under  -
went randomization. Of these patients, 459 (49.0%)
were initially randomized to the EZE + statin group
and 477 (51.0%) to the STAT2 group. A total of 
161 patients (33.8%) in the STAT2 group were
converted to the EZE + statin group: 150 (93.2%)
because of patient or physician concerns about the
tolerance of higher statin doses, and 11 (6.8%)
because they were at the maximum statin dose.
Therefore, the final treatment allocation was 620
patients (66.2%)  in the EZE + statin group and 316
patients (33.8%) in the STAT2 group. No differences
with respect to baseline characteristics between
the STAT2 patients who were converted to the EZE
+ statin group and those who were maintained in
the STAT2 group were observed. There were 51
patients (5.4%), 34 (5.5%) in the EZE + statin group
and 17 (5.4%) in the STAT2 group, who were
withdrawn prior to the 6-week final assessment.
Reasons for withdrawal were as follows: loss to
follow-up for 30 (3.2%), adverse events for 15 (1.6%),
withdrawal of consent for 5 (0.5%), while one
patient in the EZE + statin group was withdrawn
due to intolerance to the statin. 
As summarized in Table I, demographics and
baseline clinical characteristics for the ITT
population exhibited no significant differences
between groups. The mean (SD) age of the study
sample was 63 (11.3) years while 62.3% were male.
A total of 859 patients (91.8%) were classified as
being at high (≥ 20%) 10-year risk for CAD on the
basis of confirmed diabetes or atherosclerotic
disease and the remaining 77 (8.2%) were classified
Statin Patients,T otal daily statin dose, n (%)
n (%)†
10 mg2 0  mg4 0  mg8 0  mg
EZE + statin STAT2 EZE + statin STAT2 EZE + statin STAT2 EZE + statin STAT2
Atorvastatin 491 (52.5) 100 (16.1) 82 (25.9) 117 (18.9) 67 (21.2) 75 (12.1) 24 (7.6) 15 (2.4) NA
Simvastatin 167 (17.8) 14 (2.3) 16 (5.1) 45 (7.3) 19 (6.0) 54 (8.7) 10 (3.2) 4 (0.6) NA
Rosuvastatin 162 (17.3) 71 (11.5) 39 (12.3) 25 (4.0) 10 (3.2) 7 (1.1) NA NA NA
Pravastatin 81 (8.7) 3 (0.5) 1 (0.3) 21 (3.4) 24 (7.6) 19 (3.1) 7 (2.2) 4 (0.6) NA
Lovastatin 27 (2.9) 2 (0.3) NA 7 (1.1) 6 (1.9) 8 (1.3) 3 (0.9) 1 (0.2) NA
Fluvastatin 8 (0.9) NA NA 2 (0.4) 2 (0.7) 1 (0.2) 2 (0.7) 1 (0.2) NA
Total 936 (100) 190 (30.6) 138 (43.7) 217 (35.0) 128 (40.5) 164 (26.5) 46 (14.6) 25 (4.0) NA
Table II. Statin therapy at baseline*
*Before dose doubling, †Percentages are out of 936 patients enrolled: 620 in the EZE + statin group and 316 in the STAT2 group, §One patient
reported taking atorvastatin 5 mg/day, 3 patients were taking 30 mg/day and 7 patients were taking 60 mg/day; 1 patient each reported taking
simvastatin 5 mg/day, 30 mg/day, 50 mg/day, and 2 patients reported taking simvastatin 60 mg/day; 8 patients reported taking rosuvastatin 
5 mg/day and 1 patient each reported taking 30 mg/day and 60 mg/day; 1 patient each reported taking a dose of 30 mg/day and 60 mg/day of
pravastatinArch Med Sci 5, October / 2011 771
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as high risk on the basis of the Framingham model.
There were 212 patients (22.6%) with diabetes but
not the metabolic syndrome, 106 (11.3%) with the
metabolic syndrome but not diabetes, 265 (28.3%)
with both diabetes mellitus and the metabolic
syndrome and 353 (37.7%) with neither diabetes
nor the metabolic syndrome. The profile of statin
therapy at baseline is shown in Table II, with more
than half (52.5%) of the study subjects taking
atorvastatin, followed by simvastatin (17.8%),
rosuvastatin (17.3%) and pravastatin (8.7%).
Lipid profile
After 6 weeks of treatment, patients in the EZE
+ statin group experienced a significantly larger
reduction in LDL-C (–30.8% vs. –18.4% in EZE + statin
and STAT2, respectively), TC (–20.5% vs. –11.9% in
EZE + statin and STAT2, respectively), TG (–8.6% vs.
–0.8% in EZE + statin and STAT2, respectively) and
TC/HDL-C ratio (–19.4% vs. –11.2% in EZE + statin
and STAT2, respectively) (Table III). Changes in 
HDL-C, however, were not significantly different
between the two groups (0.6% vs. 1.1% in EZE +
statin and STAT2, respectively). These differences
were observed for both the total study sample and
all patient subgroups. Similar results were observed
for the subgroup of patients who converted to the
EZE + statin group (data not shown).
Multivariate linear regression analysis was
further used to adjust the between-group diffe  -
rences with respect to the percent change in 
LDL-C during the six-week treatment period for the
effect of the baseline statin dose. This analysis
indicated that co-administration of ezetimibe had
a significant effect (p < 0.001) on reducing LDL-C by
an additional 19.7% (SE: 1.36) over and above the
statin effect (Table IVA). The results also showed
that for every doubling of the baseline statin dose
used, the additional decrease in LDL-C is 5.4% (SE:
0.52). Table IVB summarizes the least-squares mean
esti  mates of the adjusted mean percent reduction
in LDL-C for the two treatment groups by baseline
statin dose. These results show that for the sample
as a whole the adjusted mean (SD) percent
decrease in LDL-C after co-administration of
ezetimibe with the current statin was 30.8% (4.95)
compared to a mean (SD) decrease of 9.3% (3.87)
for doubling the statin dose (p < 0.001). The
difference was consistent across all statin doses. 
After 6 weeks of treatment, 70% of patients in
the EZE + statin group and 48% of patients in the
STAT2 group who completed the study achieved
target LDL-C levels of less than 2.5 mmol/l 
(odds ratio [OR] 2.45, 95% CI 1.85-3.24, p < 0.001).
Similarly, a significantly higher proportion of
patients in the EZE + statin group (40%) compared
with the STAT2 group (18%) achieved final serum
LDL-C levels less than 2.0 mmol/l (OR 2.97, 95% CI
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2.14-4.13, p < 0.001). Similar results were observed
for all four patient subgroups analyzed (Figure 1).
Safety
The incidence and profile of adverse events
between the study groups were in general similar
between the two groups, with the exception of
a higher incidence of myalgia and muscle spasms
in patients in the STAT2 group (2.8% and 0.9% of
patients, respectively) compared with the EZE +
statin group (0.8% and 0% of patients, respectively).
A total of 62 non-serious adverse events (NSAEs)
were reported by 42 patients (6.8%)  in the EZE +
statin group. Of these, 16 (25.8%) NSAEs were
reported by 16 (9.9%) of the 161 patients who were
converted from the STAT2 to the EZE + statin group.
There were 22 NSAEs reported by 18 patients (5.7%)
in the STAT2 group. The majority (97.6%) of the
treatment-emergent NSAEs were mild or moderate
in severity. Two (2.4%) treatment-emergent NSAEs
of severe intensity, diarrhoea and abdominal pain,
were reported by one patient in the EZE + statin
group. Two patients in the EZE + statin group 
(1 randomized and 1 converted) experienced non-
specified increases in hepatic enzymes. No serious
adverse events were reported in this trial. 
Discussion 
Although statin treatment is the predominant
lipid-lowering strategy, a significant proportion of
patients with hypercholesterolemia do not achieve
target LDL-C levels on statin monotherapy [4-6].
Combination of ezetimibe with low-dose statin has
been shown to be effective in improving the lipid
profile in the context of controlled clinical trials,
providing an additional 20% to 25% reduction 
in low density lipoprotein cholesterol (LDL-C)
compared with statin monotherapy [23, 24]. In this
study we compared the efficacy and safety of
ezetimibe added to the existing statin regimen with
that of doubling the dose of the statin, in a real-life
setting; patients were recruited from physicians’
practices regardless of their treating statin and they
continued to receive their existing statin, either in
combination with ezetimibe or at a double dose,
throughout the course of the study.
The results of the EZE(STAT)2 study indicate that
co-administration of ezetimibe 10 mg/day with any
statin regimen is more effective in reducing serum
Variable Coefficient Value of p
Estimate SE
Group* –19.66 1.36 < 0.001
Baseline statin dose† –5.41 0.52 < 0.001
Table IVA. Multivariate linear regression analysis
results
Baseline statin  Treatment group, LS mean (SD)
dose [mg/day] EZE + statin STAT2 All patients
10‡ –25.0 (0.05) –5.4 (0.01) –16.9 (9.69)
20£ –30.5 (0.03) –10.8 (0.05) –23.2 (9.52)
40 –35.9 (0.05) –16.2 (0.11) –31.3 (8.37)
80€ –41.4 (0.05) NA –41.4 (0.05)
Total –30.8 (4.95) –9.3 (3.87) –23.5 (11.22)
Table IVB. Least-squares mean estimates of percent
change in LDL-C
Multivariate linear regression dependent variable: percent change in
LDL-C during 6-week treatment period; independent variables:
treatment group, baseline statin dose, SE – standard error, LS mean –
least-squares mean, *Group –  EZE +statin = 1, STAT2 = 0, †Baseline
statin dose: 10 mg/day = 1, 20 mg/day = 2, 40 mg/day = 3, 80 mg/day
= 4, ‡Includes 10 patients who reported taking a statin dose of 
5 mg/day, £Includes 6 patients who reported taking a statin dose 
of 30 mg/day, €Includes 12 patients who reported taking a statin dose
of 50 mg/day or 60 mg/day
Final LDL-C < 2.5 mmol/l Final LDL-C < 2.0 mmol/l
EZE + statin STAT2
Total DM DM, MS, Neither
and MS no MS no DM DM nor MS
Total DM DM, MS, Neither
and MS no MS no DM DM nor MS
p < 0.001 p = 0.003 p = 0.011 p = 0.006 p < 0.001
p < 0.001 p < 0.001
p < 0.001
p = 0.045
p < 0.001
Figure 1. Final LDL-C targets by treatment group
DM – diabetes mellitus, MS – metabolic syndrome
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%
]
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LDL-C compared to doubling of the statin dose
(change in LDL-C levels: 30.9% vs. 18.5% in the EZE
+ statin and STAT2 group, respectively, or 30.8% vs.
9.3%, respectively, when adjusting for the statin
dose; % of patients achieving LDL-C < 2.5 mmol/l:
70% vs. 48%, respectively). Moreover, significantly
more patients in the EZE + statin group achieved
the LDL-C targets of < 2.5 and < 2.0 mmol/l
currently recommended by the European Society
of Cardiology (ESC) and the US treatment
guidelines, or the Canadian Cardiovascular Society,
respectively [7, 25, 26]. In addition, co-administration
of ezetimibe with statins produced a more profound
beneficial effect on the patient’s overall lipid profile
(TC, TG, TC/HDL-C ratio) compared with doubling
the statin dose. The above-mentioned differences
were observed across patient subgroups with
diabetes and/or the metabolic syndrome that are
at increased risk for cardiovascular disease. Our
results are in agreement with recent studies
showing a similar lipid-lowering beneficial effect of
co-administering ezetimibe with atorvastatin [9, 10,
14] and simvastatin [11-13].
Ezetimibe co-administered with statin was
generally well tolerated, with a similar safety profile
and incidence of adverse events to the statin
treatment, again in agreement with recent studies
[9-14]. The only exception was a higher incidence
of myalgia and muscle spasms observed in the
STAT2 group, an effect that has been previously
associated with high doses of statins [16, 17].
Reduction of serum LDL-C levels is the primary
factor in preventing coronary heart disease [27]. In
addition to their cholesterol-reducing function,
statins exert additional pleiotropic effects such as
improving endothelial dysfunction, thrombosis and
vascular inflammation [28]. Our study was not
designed to define the effect of ezetimibe on these
parameters. However, recent studies indicate that
ezetimibe may also have similar pleiotropic effects
[29-32] and additional trials are ongoing which will
further examine the impact of ezetimibe on these
effects [33-35].
In conclusion, our study demonstrates that, in
patients at high risk for coronary artery disease who
have not achieved the LDL-C target with statin
monotherapy, co-administration of ezetimibe is
a well-tolerated and more effective strategy in
improving the lipid profile compared with doubling
the existing statin dose.
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